Eric Sullivan
Director/Board Member at CHIMERIC THERAPEUTICS LIMITED
Net worth: - $ as of 30/03/2024
Profile
Eric M.
Sullivan currently works at Chimeric Therapeutics Ltd.
(Australia), as Non-Executive Director from 2023 and Convergent Therapeutics, Inc., as Chief Financial Officer from 2023.
Mr. Sullivan also formerly worked at bluebird bio, Inc., as Chief Accounting Officer, VP-Finance & Treasurer from 2016 to 2017, TCR2 Therapeutics, Inc., as Chief Financial Officer, Triplet Therapeutics, Inc., as President, Chief Operating & Financial Officer, and Gemini Therapeutics, Inc., as Senior Vice President.
Mr. Sullivan received his undergraduate degree from Bentley University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
13/02/2024 | 0 ( -.--% ) | - $ | 30/03/2024 |
Eric Sullivan active positions
Companies | Position | Start |
---|---|---|
CHIMERIC THERAPEUTICS LIMITED | Director/Board Member | 29/08/2023 |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Director of Finance/CFO | 31/08/2023 |
Former positions of Eric Sullivan
Companies | Position | End |
---|---|---|
BLUEBIRD BIO, INC. | Comptroller/Controller/Auditor | 03/08/2017 |
GEMI THER | Corporate Officer/Principal | - |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA. | President | - |
TCR2 THERAPEUTICS INC. | Director of Finance/CFO | - |
Training of Eric Sullivan
Bentley University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
CHIMERIC THERAPEUTICS LIMITED | Health Technology |
Private companies | 4 |
---|---|
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA. | Health Services |
Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Eric Sullivan